IP Library › Granted Patent US 12,351,639
Granted Patent B2
US 12,351,639 · App. 18/163,667 · Granted Jul 8, 2025

Anti-CD30 antibodies

Inventors: Jeffrey A. Medin (Shorewood, WI); Mary L Faber (New Berlin, WI); Everett R. Tate (Greendale, WI); Robyn A. A. Oldham (Milwaukee, WI)
Assignees: The Medical College of Wisconsin, Inc.; University of Virginia Patent Foundation
C07K16/2878A61K39/3955A61K47/6849A61P35/00A61P35/02C07K14/7051C07K16/462C07K19/00C07K14/70578C07K2317/24C07K2317/41C07K2317/51C07K2317/54C07K2317/55C07K2317/565C07K2317/622C07K2317/76C07K2319/02C07K2319/03C07K2319/30C07K2319/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,639
App. No.
18/163,667
Granted
Jul 8, 2025
Kind
B2
Abstract

The present invention provides novel antibodies and antigen binding fragments thereof that bind to human CD30. Also presented are single chain variable antibodies, chimeric antigen receptors and uses thereof. Methods of treating cancer are also disclosed.

Claims (108)

1. An isolated antibody or antigen binding fragment thereof capable of binding human CD30 comprising:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 85% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 85% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 85% similarity to SEQ ID NO: 4, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 85% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO:7 or a sequence with at least 85% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8 or a sequence with at least 85% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 85% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 85% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 85% similarity to SEQ ID NO: 12, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 85% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 85% similarity to SEQ ID NO: 15, and a CDRH3 region of GAY or a sequence with at least 85% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 85% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 85% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 85% similarity to SEQ ID NO: 20, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 85% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 85% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 85% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 85% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 85% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 85% similarity to SEQ ID NO: 28, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 85% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 85% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 85% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 85% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 85% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 85% similarity to SEQ ID NO: 36, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 85% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO:39 or a sequence with at least 85% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 85% similarity to SEQ ID NO: 40.

2. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or fragment is a monoclonal antibody, a humanized antibody, a single chain variable fragment (scFv) antibody, a single domain antibody, an or a chimeric antibody.

3. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the antibody or fragment thereof is engrafted within a full IgG scaffold or a scFv scaffold.

4. The isolated antibody or antigen binding fragment thereof of claim 3 , wherein the scaffold is human in origin.

5. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the antigen binding fragment thereof is a single chain variable fragment (scFv), and wherein the light chain and heavy chain are linked via a linker amino acid sequence.

6. The isolated antibody or antigen binding fragment of claim 5 , wherein the single chain variable fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 42 or a sequence with at least 85% similarity to SEQ ID NO: 42, SEQ ID NO: 44 or a sequence with at least 85% similarity to SEQ ID NO: 44, SEQ ID NO: 46 or a sequence with at least 85% similarity to SEQ ID NO: 46, SEQ ID NO: 48 or a sequence with at least 85% similarity to SEQ ID NO: 48, SEQ ID NO: 50 or a sequence with at least 85% similarity to SEQ ID NO: 50, and SEQ ID NO: 52 or a sequence with at least 85% similarity to SEQ ID NO: 52.

7. A composition comprising the antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.

8. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the CD30 antibody or antigen binding fragment thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 90% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 90% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 90% similarity to SEQ ID NO: 4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 90% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO: 7 or a sequence with at least 90% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8 or a sequence with at least 90% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 90% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 90% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 90% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 90% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 90% similarity to SEQ ID NO:15, and a CDRH3 region of GAY or a sequence with at least 90% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 90% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 90% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 90% similarity to SEQ ID NO: 20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 90% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 90% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 90% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 90% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 90% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 90% similarity to SEQ ID NO: 28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 90% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 90% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 90% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 90% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 90% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 90% similarity to SEQ ID NO: 36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 90% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO: 39 or a sequence with at least 90% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 90% similarity to SEQ ID NO: 40.

9. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the CD30 antibody or antigen binding fragment thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 95% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 95% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 95% similarity to SEQ ID NO: 4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 95% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO: 7 or a sequence with at least 95% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8 or a sequence with at least 95% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 95% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 95% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 95% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 95% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 95% similarity to SEQ ID NO: 15, and a CDRH3 region of GAY or a sequence with at least 95% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 95% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 95% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 95% similarity to SEQ ID NO: 20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 95% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 95% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 95% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 95% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 95% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 95% similarity to SEQ ID NO: 28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 95% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 95% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 95% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 95% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 95% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 95% similarity to SEQ ID NO: 36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 95% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO: 39 or a sequence with at least 95% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 95% similarity to SEQ ID NO: 40.

10. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the CD30 antibody or antigen binding fragment thereof comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 98% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 98% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 98% similarity to SEQ ID NO: 4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 98% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO: 7 or a sequence with at least 98% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8 or a sequence with at least 98% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 98% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 98% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 98% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 98% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 98% similarity to SEQ ID NO: 15, and a CDRH3 region of GAY or a sequence with at least 98% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 98% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 98% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 98% similarity to SEQ ID NO: 20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 98% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 98% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 98% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 98% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 98% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 98% similarity to SEQ ID NO: 28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 98% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 98% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 98% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 98% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 98% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 98% similarity to SEQ ID NO: 36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 98% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO: 39 or a sequence with at least 98% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 98% similarity to SEQ ID NO: 40.

11. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO: 1 or a sequence with at least 90% similarity to SEQ ID NO: 1, and a heavy chain comprising SEQ ID NO: 5 or a sequence with at least 90% similarity to SEQ ID NO: 5;

(b) a light chain comprising SEQ ID NO: 9 or a sequence with at least 90% similarity to SEQ ID NO: 9, and a heavy chain comprising SEQ ID NO: 13 or a sequence with at least 90% similarity to SEQ ID NO: 13;

(c) a light chain comprising SEQ ID NO: 17 or a sequence with at least 90% similarity to SEQ ID NO: 17, and a heavy chain comprising SEQ ID NO: 21 or a sequence with at least 90% similarity to SEQ ID NO: 21;

(d) a light chain comprising SEQ ID NO: 25 or a sequence with at least 90% similarity to SEQ ID NO: 25, and a heavy chain comprising SEQ ID NO: 29 or a sequence with at least 90% similarity to SEQ ID NO: 29; or

(e) a light chain comprising SEQ ID NO: 33 or a sequence with at least 90% similarity to SEQ ID NO: 33, and a heavy chain comprising SEQ ID NO: 37 or a sequence with at least 90% similarity to SEQ ID NO: 37.

12. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO: 1 or a sequence with at least 95% similarity to SEQ ID NO: 1, and a heavy chain comprising SEQ ID NO: 5 or a sequence with at least 95% similarity to SEQ ID NO: 5;

(b) a light chain comprising SEQ ID NO: 9 or a sequence with at least 95% similarity to SEQ ID NO: 9, and a heavy chain comprising SEQ ID NO: 13 or a sequence with at least 95% similarity to SEQ ID NO: 13;

(c) a light chain comprising SEQ ID NO: 17 or a sequence with at least 95% similarity to SEQ ID NO: 17, and a heavy chain comprising SEQ ID NO: 21 or a sequence with at least 95% similarity to SEQ ID NO: 21;

(d) a light chain comprising SEQ ID NO:25 or a sequence with at least 95% similarity to SEQ ID NO: 25, and a heavy chain comprising SEQ ID NO: 29 or a sequence with at least 95% similarity to SEQ ID NO: 29; or

(e) a light chain comprising SEQ ID NO: 33 or a sequence with at least 95% similarity to SEQ ID NO: 33, and a heavy chain comprising SEQ ID NO: 37 or a sequence with at least 95% similarity to SEQ ID NO: 37.

13. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO: 1 or a sequence with at least 98% similarity to SEQ ID NO: 1, and a heavy chain comprising SEQ ID NO: 5 or a sequence with at least 98% similarity to SEQ ID NO: 5;

(b) a light chain comprising SEQ ID NO: 9 or a sequence with at least 98% similarity to SEQ ID NO: 9, and a heavy chain comprising SEQ ID NO: 13 or a sequence with at least 98% similarity to SEQ ID NO: 13;

(c) a light chain comprising SEQ ID NO: 17 or a sequence with at least 98% similarity to SEQ ID NO: 17, and a heavy chain comprising SEQ ID NO: 21 or a sequence with at least 98% similarity to SEQ ID NO: 21;

(d) a light chain comprising SEQ ID NO: 25 or a sequence with at least 98% similarity to SEQ ID NO: 25, and a heavy chain comprising SEQ ID NO: 29 or a sequence with at least 98% similarity to SEQ ID NO: 29; or

(e) a light chain comprising SEQ ID NO: 33 or a sequence with at least 98% similarity to SEQ ID NO: 33, and a heavy chain comprising SEQ ID NO: 37 or a sequence with at least 98% similarity to SEQ ID NO: 37.

14. The isolated antibody or antigen binding fragment thereof of claim 1 , wherein the anti-CD30 antibody or antigen binding portion thereof comprises a light chain and a heavy chain comprising:

(a) a light chain comprising SEQ ID NO: 1 and a heavy chain comprising SEQ ID NO: 5;

(b) a light chain comprising SEQ ID NO: 9 and a heavy chain comprising SEQ ID NO: 13;

(c) a light chain comprising SEQ ID NO: 17 and a heavy chain comprising SEQ ID NO: 21;

(d) a light chain comprising SEQ ID NO: 25 and a heavy chain comprising SEQ ID NO: 29; or

(e) a light chain comprising SEQ ID NO: 33 and a heavy chain comprising SEQ ID NO: 37.

15. The isolated antibody or antigen binding fragment of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a single chain variable fragment comprising:

SEQ ID NO: 42 or a sequence with at least 90% similarity to SEQ ID NO: 42;

SEQ ID NO: 44 or a sequence with at least 90% similarity to SEQ ID NO: 44;

SEQ ID NO: 46 or a sequence with at least 90% similarity to SEQ ID NO: 46;

SEQ ID NO: 48 or a sequence with at least 90% similarity to SEQ ID NO: 48;

SEQ ID NO: 50 or a sequence with at least 90% similarity to SEQ ID NO: 50; or

SEQ ID NO: 52 or a sequence with at least 90% similarity to SEQ ID NO: 52.

16. The isolated antibody or antigen binding fragment of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a single chain variable fragment comprising:

SEQ ID NO: 42 or a sequence with at least 95% similarity to SEQ ID NO: 42;

SEQ ID NO: 44 or a sequence with at least 95% similarity to SEQ ID NO: 44;

SEQ ID NO: 46 or a sequence with at least 95% similarity to SEQ ID NO: 46;

SEQ ID NO: 48 or a sequence with at least 95% similarity to SEQ ID NO: 48;

SEQ ID NO: 50 or a sequence with at least 95% similarity to SEQ ID NO: 50; or

SEQ ID NO: 52 or a sequence with at least 95% similarity to SEQ ID NO: 52.

17. The isolated antibody or antigen binding fragment of claim 1 , wherein the anti-CD30 antibody or antigen binding fragment thereof comprises a single chain variable fragment comprising:

SEQ ID NO: 42 or a sequence with at least 98% similarity to SEQ ID NO: 42;

SEQ ID NO: 44 or a sequence with at least 98% similarity to SEQ ID NO: 44;

SEQ ID NO: 46 or a sequence with at least 98% similarity to SEQ ID NO: 46;

SEQ ID NO: 48 or a sequence with at least 98% similarity to SEQ ID NO: 48;

SEQ ID NO: 50 or a sequence with at least 98% similarity to SEQ ID NO: 50; or

SEQ ID NO: 52 or a sequence with at least 98% similarity to SEQ ID NO: 52.

18. A chimeric antigen receptor (CAR) comprising a CD30 binding domain, a hinge region, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain,

wherein the intracellular domain comprises a CD3 zeta chain, and

wherein the CD30 binding domain comprises:

(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2 or a sequence with at least 85% similarity to SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3 or a sequence with at least 85% similarity to SEQ ID NO: 3, and a CDRL3 region of SEQ ID NO: 4 or a sequence with at least 85% similarity to SEQ ID NO: 4, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6 or a sequence with at least 85% similarity to SEQ ID NO: 6, a CDRH2 region of SEQ ID NO: 7 or a sequence with at least 85% similarity to SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO:8 or a sequence with at least 85% similarity to SEQ ID NO: 8;

(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 85% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 85% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO: 12 or a sequence with at least 85% similarity to SEQ ID NO: 12, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 85% similarity to SEQ ID NO: 14, a CDRH2 region of SEQ ID NO: 15 or a sequence with at least 85% similarity to SEQ ID NO: 15, and a CDRH3 region of GAY or a sequence with at least 85% similarity to GAY;

(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 18 or a sequence with at least 85% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 85% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO: 20 or a sequence with at least 85% similarity to SEQ ID NO: 20, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 22 or a sequence with at least 85% similarity to SEQ ID NO: 22, a CDRH2 region of SEQ ID NO: 23 or a sequence with at least 85% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO: 24 or a sequence with at least 85% similarity to SEQ ID NO: 24;

(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 26 or a sequence with at least 85% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO: 27 or a sequence with at least 85% similarity to SEQ ID NO: 27, and a CDRL3 region of SEQ ID NO: 28 or a sequence with at least 85% similarity to SEQ ID NO: 28, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 30 or a sequence with at least 85% similarity to SEQ ID NO: 30, a CDRH2 region of SEQ ID NO: 31 or a sequence with at least 85% similarity to SEQ ID NO: 31, and a CDRH3 region of SEQ ID NO: 32 or a sequence with at least 85% similarity to SEQ ID NO: 32; or

(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 34 or a sequence with at least 85% similarity to SEQ ID NO: 34, a CDRL2 region of SEQ ID NO: 35 or a sequence with at least 85% similarity to SEQ ID NO: 35, and a CDRL3 region of SEQ ID NO: 36 or a sequence with at least 85% similarity to SEQ ID NO: 36, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 38 or a sequence with at least 85% similarity to SEQ ID NO: 38, a CDRH2 region of SEQ ID NO: 39 or a sequence with at least 85% similarity to SEQ ID NO: 39, and a CDRH3 region of SEQ ID NO: 40 or a sequence with at least 85% similarity to SEQ ID NO: 40.

19. The CAR of claim 18 , wherein the CAR comprises a single chain variable fragment comprising an amino acid sequence of SEQ ID NO: 42 or a sequence with at least 85% similarity to SEQ ID NO: 42, SEQ ID NO: 44 or a sequence with at least 85% similarity to SEQ ID NO: 44, SEQ ID NO: 46 or a sequence with at least 85% similarity to SEQ ID NO: 46, SEQ ID NO: 48 or a sequence with at least 85% similarity to SEQ ID NO: 48, SEQ ID NO: 50 or a sequence with at least 85% similarity to SEQ ID NO: 50, or SEQ ID NO: 52 or a sequence with at least 85% similarity to SEQ ID NO: 52.

20. An isolated antibody or antigen binding fragment thereof which binds human CD30 comprising a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 2, a CDRL2 region of SEQ ID NO: 3, a CDRL3 region of SEQ ID NO: 4, and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 6, a CDRH2 region of SEQ ID NO: 7, and a CDRH3 region of SEQ ID NO: 8.

21. The antibody or antigen binding fragment thereof of claim 20 comprising a light chain comprising SEQ ID NO: 1 or a sequence with at least 95% similarity to SEQ ID NO: 1, and a heavy chain comprising SEQ ID NO: 5 or a sequence with at least 95% similarity to SEQ ID NO: 5.

22. The antibody or antigen binding fragment thereof of claim 20 comprising a light chain comprising SEQ ID NO: 1 or a sequence with at least 98% similarity to SEQ ID NO: 1, and a heavy chain comprising SEQ ID NO: 5 or a sequence with at least 98% similarity to SEQ ID NO: 5.

23. The antibody or antigen binding fragment thereof of claim 20 comprising a light chain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 5.

24. The antibody or antigen binding fragment thereof of claim 20 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 42 or a sequence with at least 85% similarity to SEQ ID NO: 42 or 44.

25. The antibody or antigen binding fragment thereof of claim 20 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 42 or a sequence with at least 90% similarity to SEQ ID NO: 42 or 44.

26. The antibody or antigen binding fragment thereof of claim 20 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 42 or a sequence with at least 95% similarity to SEQ ID NO: 42 or 44.

27. The antibody or antigen binding fragment thereof of claim 20 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 42 or a sequence with at least 98% similarity to SEQ ID NO: 42 or 44.

28. The antibody or antigen binding fragment thereof of claim 20 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 42 or 44.

29. The antibody or antigen binding fragment thereof of claim 20 , wherein the antibody is a monoclonal antibody, a humanized antibody, a single chain variable fragment (scFv), a single domain antibody, or a chimeric antibody.

30. The antibody or antigen binding fragment thereof of claim 20 , wherein the antibody or antigen-binding fragment thereof is engrafted within a full IgG scaffold or a scFv scaffold.

31. The antibody or antigen binding fragment thereof of claim 20 , wherein the scaffold is human in origin.

32. The antibody or antigen binding fragment thereof of claim 20 , wherein the antigen binding fragment thereof is a single chain variable fragment (scFv) wherein the light chain and heavy chain are linked via a linker amino acid sequence.

33. A composition comprising the antibody or antigen binding fragment thereof of claim 20 and a pharmaceutically acceptable carrier.

34. An isolated antibody or antigen binding fragment thereof which binds human CD30 comprising a light chain variable domain comprising a CDRL1 region comprising the sequence of SEQ ID NO: 10, a CDRL2 region comprising the sequence of SEQ ID NO: 11, and a CDRL3 region comprising the sequence of SEQ ID NO: 12, and a heavy chain variable domain comprising the sequence of SEQ ID NO: 14, a CDRH2 region comprising the sequence of SEQ ID NO: 15, and a CDRH3 region comprising the sequence of GAY.

35. The antibody or antigen binding fragment thereof of claim 34 comprising a light chain comprising SEQ ID NO: 9 or a sequence with at least 95% similarity to SEQ ID NO: 9, and a heavy chain comprising SEQ ID NO: 13 or a sequence with at least 95% similarity to SEQ ID NO: 13.

36. The antibody or antigen binding fragment thereof of claim 34 comprising a light chain comprising SEQ ID NO: 9 or a sequence with at least 98% similarity to SEQ ID NO: 9, and a heavy chain comprising SEQ ID NO: 13 or a sequence with at least 98% similarity to SEQ ID NO: 13.

37. The antibody or antigen binding fragment thereof of claim 34 comprising a light chain comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 13.

38. The antibody or antigen binding fragment thereof of claim 34 comprising a single chain variable fragment comprising the amino acid sequence of SEQ ID NO: 46.

39. The antibody or antigen binding fragment thereof of claim 34 , wherein the antibody is a monoclonal antibody, a humanized antibody, a single chain variable fragment (scFv), a single domain antibody, or a chimeric antibody.

40. The antibody or antigen binding fragment thereof of claim 34 , wherein the antibody or antigen-binding fragment thereof is engrafted within a full IgG scaffold or a scFv scaffold.

41. The antibody or antigen binding fragment thereof of claim 34 , wherein the scaffold is human in origin.

42. The antibody or antigen binding fragment thereof of claim 34 , wherein the antigen binding fragment thereof is a single chain variable fragment (scFv) wherein the light chain and heavy chain are linked via a linker amino acid sequence.

43. A composition comprising the antibody or antigen binding fragment thereof of claim 34 and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2023
From: MEDIN, JEFFREY A.; FABER, MARY L.; TATE, EVERETT R.; OLDHAM, ROBYN A.A.
To: THE MEDICAL COLLEGE OF WISCONSIN, INC.
Reel/Frame 062582/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2023
From: THE MEDICAL COLLEGE OF WISCONSIN
To: UNIVERSITY OF VIRGINIA PATENT FOUNDATION D/B/A THE UNIVERSITY OF VIRGINIA LICENSING & VENTURES GROUP
Reel/Frame 062582/0336 →
Continuity (3)
Continuation 16580483 · Sep 24, 2019
Provisional Application 62735508 · Sep 24, 2018
Related Publication 20230235071A1 · Jul 27, 2023
References Cited (57)
US 7090843B1 · Francisco · 2006 [cited by applicant]
US 7446190B2 · Sadelain · 2008 [cited by applicant]
US 8088377B2 · Keler · 2012 [cited by applicant]
US 11584799B2 · Medin · 2023 [cited by examiner]
US 11667721B2 · Medin · 2023 [cited by examiner]
US 20130071414A1 · Dotti · 2013 [cited by applicant]
US 20130287748A1 · June · 2013 [cited by applicant]
US 20160200824A1 · Chmielewski · 2016 [cited by applicant]
US 20200095330A1 · Medin et al. · 2020 [cited by applicant]
WO 2003059282A2 · 2003 [cited by applicant]
WO 2014099671A1 · 2014 [cited by applicant]
WO 2016134284A1 · 2016 [cited by applicant]
WO 2017066122A1 · 2017 [cited by applicant]
European Patent Office, Communication Pursuant to Article 94(3) EPC, Application No. 19783839.4, Apr. 30, 2024, 5 pages. [cited by applicant]
ADC Review. Anonymous. Journal of Antibody-drug Conjugates: Monomethyl auristatin E (MMAE). Last updated Mar. 7, 2015. [cited by applicant]
Ahmed, N., et al. “HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.” Clinical Cancer Research 16.2 (2010): 474-485. [cited by applicant]
Altschul, S. F., et al. “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.” Nucleic acids research 25.17 (1997): 3389-3402. [cited by applicant]
Batzer, M. A., et al. “Enhanced evolutionary PCR using oligonucleotides with inosine at the 3′-terminus.” Nucleic acids research 19.18 (1991): 5081. [cited by applicant]
Brentjens, Re. J., et al. “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.” Nature medicine 9.3 (2003): 279-286. [cited by applicant]
Carde, P., et al. “Immunoscintigraphy of Hodgkin's disease: in vivo use of radiolabelled monoclonal antibodies derived from Hodgkin cell lines.” European Journal of Cancer and Clinical Oncology 26.4 (1990): 474-479. [cited by applicant]
Chekmasova, A. A., et al. “Enhanced Antitumor Efficacy of MUC-16 Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model of Ovarian Cancer.” Blood. (2011): 4176-4176. [cited by applicant]
Chen, R et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 128:1562-1566. [cited by applicant]
Chiarle, R., et al. CD30 in normal and neoplastic cells. Clin. Immunol. 90(2):157-164 (1999). [cited by applicant]
Chicaybam, L. et al. “Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.” International reviews of immunology 30.5-6 (2011): 294-311. [cited by applicant]
Dabir, S., et al. CD30 is a potential therapeutic target in malignant mesothelioma. Molecular cancer therapeutics 14.3 (2015): 740-746. [cited by applicant]
Diamantis, N. et al. “Antibody-drug conjugates—an emerging class of cancer treatment.” British journal of cancer 114.4 (2016): 362-367. [cited by applicant]
Friedrich, M et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific Tcell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 13(6):1549-57. [cited by applicant]
Froese, P., et al. “Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines.” The Journal of Immunology 139.6 (1987): 2081-2087. [cited by applicant]
Gaudio, F., et al. Outcome of very late relapse in patients with Hodgkin's lymphomas. Advances in hematology 2011 (2010). [cited by applicant]
Gopal, A. K., et al. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma. Cancer 113.6 (2008): 1344-1350. [cited by applicant]
International Searching Authority, International Search Report and Written Opinion for application PCT/US2019/052618, mailed on Nov. 28, 2019. [cited by applicant]
Johnsson, B., et al. “Comparison of methods for immobilization to carboxymethyl dextran sensor surfaces by analysis of the specific activity of monoclonal antibodies.” Journal of Molecular Recognition 8.1-2 (1995): 125-… [cited by applicant]
Johnsson, B., et al. “Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors.” Analytical biochemistry 198.2 (1991): 268-277. [cited by applicant]
Jönsson, U., et al. “Introducing a biosensor based technology for real-time biospecific interaction analysis.” Annales de biologie clinique. vol. 51. No. 1. 1993. pp. 19-26. [cited by applicant]
Jonsson, U., et al. “Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology.” Biotechniques 11.5 (1991): 620-627. [cited by applicant]
Karlin, S. et al. “Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes.” Proceedings of the National Academy of Sciences 87.6 (1990): 2264-2268. [cited by applicant]
Koon, H. B. et al. “Anti-CD30 antibody-based therapy.” Current opinion in oncology 12.6 (2000): 588-593. [cited by applicant]
Kung Sutherland, MS et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013122(8):1455-1463. [cited by applicant]
Lum, L. G., et al. “Targeting T cells with bispecific antibodies for cancer therapy.” BioDrugs 25.6 (2011): 365-379. [cited by applicant]
Lum, L. G., et al. “CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.” Biology of Blood and Marrow Transplantation 19.6 (2013): 925-933. [cited by applicant]
Ohtsuka, E., et al. “An alternative approach to deoxyoligonucleotides as hybridization probes by insertion of deoxyinosine at ambiguous codon positions.” Journal of Biological Chemistry 260.5 (1985): 2605-2608. [cited by applicant]
Oldham, Raa, et al. Development of Novel alpha-CD30 CAR Immunotherapy for Hodgkin Lymphoma. Presented at the Fifth Annual Pediatric Cancer Symposium, Milwaukee, WI. May 10, 2018. [cited by applicant]
Rossolini, G. M. et al. “Use of deoxyinosine-containing primers vs degenerate primers for polymerase chain reaction based on ambiguous sequence information.” Molecular and cellular probes 8.2 (1994): 91-98. [cited by applicant]
Sabattini E, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102:83-7. [cited by applicant]
Sadelain, et al., “The Basic Principles of Chimeric Antigen Receptor Design.” Cancer Discovery, OF1-11, (2013). [cited by applicant]
Safdari, Y, et al. “Antibody humanization methods—a review and update.” Biotechnology and Genetic Engineering Reviews 29.2 (2013): 175-186. [cited by applicant]
Schwab, U, et al. “Production of a monoclonal antibody specific for Hodgkin and Sternberg—Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.” Nature 299.5878 (1982): 65-67. [cited by applicant]
Thakur, A. et al. “Cancer therapy with bispecific antibodies: Clinical experience.” Current opinion in molecular therapeutics 12.3 (2010): 340. [cited by applicant]
Valton, J., et al. “A versatile safeguard for chimeric antigen receptor T-cell immunotherapies.” Scientific reports 8.1 (2018): 1-8. [cited by applicant]
Verma, R., et al. “Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems.” Journal of immunological methods 216.1-2 (1998): 165-181. [cited by applicant]
Ward, E. S., et al. “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
Wu C-Y, et al. (“Remote control of therapeutic T cells through a small molecule-gated chimeric receptor” Science 350 (6258), Oct. 16, 2015, aab4077-9. [cited by applicant]
Wu, X., et al. (2017). kpLogo: positional k-mer analysis reveals hidden specificity in biological sequences. Nucleic Acids Research. doi: 10.1093/nar/gkx323. [cited by applicant]
Younes, A et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology. 2012 30(18):2183-2189. [cited by applicant]
Zhong, X-S, et al. “Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.” Molecular Therapy 18.2 (2010): 413-420. [cited by applicant]
Thakur, A. Optimize Synergistic Target Selection to Maximize Therapeutic Benefit. Presented at World Bispecific Conference. Sep. 30, 2016. Boston, MA USA. [cited by applicant]
Brudno, J., Kochenderfer, J. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 15, 31-46 (2018). https://doi.org/10.1038/nrclinonc.2017.128. [cited by applicant]